Perjeta Injection (Pertuzumab): Advanced HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology
In the precision-driven oncology landscape of 2026, Perjeta Injection (active ingredient Pertuzumab) represents a breakthrough in targeted biological therapy. As a recombinant humanized monoclonal antibody, Perjeta is the first in a class of agents called HER2-dimerization inhibitors (HDIs), specifically designed to work in synergy with Trastuzumab to provide a more comprehensive blockade of HER2 signaling pathways.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perjeta to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain integrity and rapid logistical execution.
Technical Product Profile: Perjeta (Pertuzumab)
Perjeta targets a different epitope on the HER2 receptor than Trastuzumab, effectively preventing HER2 from pairing (dimerizing) with other HER receptors (HER1, HER3, and HER4).
Product Specifications
Active Ingredient: Pertuzumab
Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial
Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody)
Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake.
Primary Clinical Indications
Metastatic Breast Cancer (MBC): In combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen.
Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence.
Mechanism of Action: Dual HER2 Blockade
Perjeta’s unique mechanism involves binding to Domain II of the HER2 extracellular domain.
Inhibition of Dimerization: Perjeta specifically inhibits the ligand-dependent HER2-HER3 heterodimerization, which is the most potent signaling pair in the HER family.
Complementary Action: While Trastuzumab binds to Domain IV to inhibit ligand-independent signaling, Perjeta blocks Domain II. Together, they provide a "dual blockade" that more effectively shuts down cancer cell growth signals.
ADCC Activation: Like other monoclonal antibodies, Perjeta induces Antibody-Dependent Cellular Cytotoxicity (ADCC) to recruit the immune system to destroy tumor cells.
Global Export Expertise: UK, USA, UAE, Australia, & South Africa
Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-value biological medications.
United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards.
United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced breast cancer care.
Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with validated, temperature-monitored shipping to Abu Dhabi and Dubai.
Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks.
South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
